Missing genetic diversity impacts variant prioritisation for rare disorders - Tallman, Sam; Moutsianas, Loukas; Nguyen, Thuy; Cho, Yoonsu; Mackintosh, Maxine; Kasperaviciute, Dalia; Brown, Matthew A; Ellingford, Jamie; Kuchenbaecker, Karoline; Silver, Matt J (medRxiv, 2024)
Whole genome sequencing identifies millions of genetic variants per individual. When applied to rare disease diagnosis, potentially pathogenic variants are prioritised for clinical interpretation, a process that may be influenced by an individual’s genetic ancestry. We analysed millions of rare protein-altering variants prioritised in 29,425 participants with rare disease from the UK 100,000 Genomes Project. We observed disparities in the number of variants prioritised across genetic ancestry groups, with an up to 3-fold increase in participants with African compared to European ancestries. Variants prioritised in participants with non-European ancestries were less likely to be assessed as pathogenic. Leveraging a cohort of 34,701 diverse genomes from the UK, we identified thousands of candidate variants that were ultra-rare or unobserved across populations in gnomAD but common among ancestry-matched individuals. Our findings highlight the importance of using reference databases that reflect patient genetic diversity when prioritising variants for rare disease diagnosis.Competing Interest StatementAll authors are employees of Genomics England Ltd.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Genomics England name gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes